Insilico Medicine secures $110 M Series E financing to advance AI-driven drug discovery innovation

Retrieved on: 2025-03-13 18:19:54

Tags for this article:

Insilico Medicine

Alex Zhavoronkov

Cybernetics

Zhavoronkov

Fosun Pharma

Artificial intelligence

Exelixis

Drug pipeline

Click the tags to see associated articles and topics

Insilico Medicine secures $110 M Series E financing to advance AI-driven drug discovery innovation. View article details on hiswai:

Summary

Insilico Medicine's $110 million Series E funding enhances its AI-driven drug discovery. Founded by Alex Zhavoronkov, it partners with Fosun Pharma and Exelixis. The investment fosters AI innovation and drug pipeline advancement in healthcare.

Article found on: www.biospectrumasia.com

View Original Article